Lakefront Biotherapeutics (GLPGF) Free Cash Flow Growth (1y) (2015 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Free Cash Flow Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn | 82.57% |
| 2 | Gilead Sciences | 181.28 Bn | 178.10 Bn | 6.22 Bn | 376.81% |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn | 9.25% |
| 4 | Regeneron Pharmaceuticals | 82.58 Bn | 74.58 Bn | 3.93 Bn | -38.10% |
| 5 | Argenx Se | 61.67 Bn | 56.48 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.58 Bn | 49.44 Bn | 52.00 Mn | 38.94% |
| 7 | Alnylam Pharmaceuticals | 34.01 Bn | 30.70 Bn | 992.69 Mn | 152.82% |
| 8 | Biogen | 31.26 Bn | 29.98 Bn | 1.96 Bn | 203.80% |
| 9 | Roivant Sciences | 29.78 Bn | 29.78 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -174.42% |
| Dec 31, 2025 | 7.41% |
| Sep 30, 2025 | -28.41% |
| Jun 30, 2025 | 31.55% |
| Mar 31, 2025 | 72.66% |
| Dec 31, 2024 | 86.16% |
| Mar 31, 2024 | -32.59% |
| Dec 31, 2023 | 13.69% |
| Mar 31, 2023 | -64.14% |
| Dec 31, 2022 | 6.15% |
| Mar 31, 2022 | 56.42% |
| Dec 31, 2021 | -12.11% |
| Jun 30, 2021 | 42.34% |
| Mar 31, 2021 | -86.59% |
| Dec 31, 2020 | -324.02% |
| Jun 30, 2020 | -96.62% |
| Mar 31, 2020 | 7.88% |
| Dec 31, 2019 | 28.22% |
| Sep 30, 2019 | 139,859.88% |
| Jun 30, 2019 | -27.23% |